An Assessment of Polypharmacy in Acute Myeloid Leukemia

Polypharmacy may adversely impact overall survival (OS) in acute myeloid leukemia (AML), particularly in patients aged younger than 60 years. This study included 399 patients with AML who were stratified by whether they had polypharmacy. Patients aged 60 years and older and who had a Karnofsky Performance Status ≤80, hematopoietic cell transplantation (HCT) comorbidity index ≥5, and adverse cytogenetics were more likely to have polypharmacy. Those with polypharmacy were less likely to receive intensity chemotherapy or HCT and had lower one-year OS compared with patients without polypharmacy (29% vs. 49%). One-year OS was worse in patients with polypharmacy aged younger than 60 years (37% vs. 65%) but not patients aged 60 years and older (26% vs. 27%).